TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Deviating the Esophagus in Atrial Fibrillation Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 - Age \< 80 yr~* Documentation of atrial fibrillation (AF)~* Referred for a first ever ablation procedure for AF (prior ablation of right-sided Typical flutter, or limited left-sided of an accessory pathway are permitted)~* General anesthesia~* All patients must understand and adhere to the requirements of the study and be willing to comply with the post study follow-up requirements.~Exclusion Criteria:~* Any reversible cause of AF (post-surgery, thyroid disorder, etc.)~* INR \> 4.0 at the time of the procedure~* H/o of severe esophageal ulcers, strictures, esophagitis or GERD~* H/o Esophageal Surgery~* Prior surgical or catheter ablation procedure for AF (except right atrial flutter ablation)~* Any evidence of esophageal diverticulum or other structural abnormalities of the esophagus seen during baseline barium esophagogram~* Significant abnormality on Swallowing Impairment Score~* Mental impairment precluding signing consent or completing follow up~* Patients with any other significant uncontrolled or unstable medical condition~* Women who are known to be pregnant or have had a positive β-HCG test 7 days prior to procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- esophageal deviation (Type: EXPERIMENTAL): esophageal deviation with IDE device during AF ablation
- temperature monitoring (Type: NO_INTERVENTION): luminal esophageal temperature monitoring, standard temperature monitoring alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. BSS greater than 4~2. BHS greater than 8~3. BDI greater than 19~4. Ability to give informed consent.~5. Active Duty military status.~6. Verified negative qualitative pregnancy test.~7. All participants must be accepted for psychiatric admission to the hospital PRIOR to consideration for enrollment in this study.~Exclusion Criteria:~1. Psychosis or Bipolar Disorder.~2. Pregnancy~3. Involuntary Status on presentation to the ED.~4. UDS positive for illicit drugs of abuse.~5. Blood Alcohol level greater than zero.~6. Previous enrollees in this treatment protocol will be excluded from repeat participation.~7. Any patient brought for command directed psychiatric evaluation.~8. Specific contraindications to the use of ketamine are as follows and under such circumstances or conditions, personnel with the following should be excluded from participation in this study:~   1. Patients with elevated intracranial pressure, uncontrolled hypertension, coronary artery disease, aneurysms, thyrotoxicosis, CHF, a recent history of head or eye injury, or angina.~  2. All personnel in whom a significant elevation of blood pressure would constitute a serious hazard to their overall health and well-being.~  3. Patients currently utilizing the following medications: conivaptan, Disatinib, peginterferon alfa-2b, quazepam, tocilizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Normal Saline Infusion (Type: PLACEBO_COMPARATOR): A single IV bolus dose of normal saline solution.
- Subanesthetic IV Bolus Ketamine (Type: EXPERIMENTAL): a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* After a restaging TURBT patients with histologically proven primary high grade (grade3) and/or pT1 transitional cell carcinoma of the bladder, with or without pTis and pTis alone are regarded as being at high risk for tumour recurrence and progression.~* Patients may enroll in this study if they are thought to have no residual disease after TURBT.~* Age 18 years or over~* Adequate bone-marrow reserve- ECOG performance status between 0 and 2~* Patients who are known PPD positive will be screened for active tuberculosis prior to starting treatment with BCG.~Exclusion Criteria:~* known allergy to BCG or MMC~* prior systemic infection with BCG~* prior or concomitant urothelial tumours of the upper urinary tract or urethra~* previous muscle-invasive (ie, stage T2 or higher) transitional-cell carcinoma of the bladder~* bladder capacity of less than 200 ml~* untreated urinary-tract infection~* severe systemic infection (ie, sepsis)~* known HIV-positivity; therapy with immunosuppressive agents~* urethral strictures that would prevent endoscopic procedures and repeated catheterisation~* upper urinary tract disease (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures a risk~* previous radiotherapy to the pelvis~* other concurrent chemotherapy~* treatment with radiotherapy-response or biological-response modifiers~* history of tuberculosis;~* other malignant diseases within 5 years of trial registration (except for adequately treated basal-cell or squamous cell skin cancer, in situ cervical cancer and any other cancer from which patients has been disease-free for 3 years);~* pregnancy or nursing~* psychological, familial, sociological, or geographical factors that would preclude study participation.~* Patients with implantable or wearable electrical devices will be excluded from this study.~* Patients with active tuberculosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Intravesical BCG and EMDA/MMC (Type: EXPERIMENTAL): Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: C1-inhibitor in Allergic ASThma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Intermittent to mild asthma according to the Global Initiative for Asthma (GINA) criteria~* Allergy for HDM documented by a positive RAST and a positive skin prick test.~* No clinically significant findings during physical examination and hematological and biochemical screening~* At spirometry FEV1 more than 70% of predicted value~* A PC20 between 0.3 - 9.6 mg/ml (corresponding with increased airway hyperreactivity)~* Able to communicate well with the investigator and to comply with the requirements of the study~* Stable asthma without the use of asthma medication 2 weeks prior to the study day. As documented by the Juniper's Asthma control questionnaire (ACQ) score \< 1,2.~* Written informed consent~* No current smoking for at least 1 year and less than 10 pack years of smoking history~Exclusion Criteria:~* Relevant comorbidity, pregnancy and/or recent surgical procedures.~* A history of smoking within the last 12 months, or regular consumption of greater than three units of alcohol per day~* Exacerbation and/ or the use of asthma medication within 2 weeks before start~* Administration of any investigational drug within 30 days of study initiation~* Donation of blood within 60 days, or loss of greater than 400 ml of blood within 12 weeks of study initiation\]~* History of venous or arterial thromboembolic disease~* History of enhanced bleeding tendency or abnormal clotting test results.~* History of serious drug-related reactions, including hypersensitivity~* Inability to maintain stable without the use of asthma medication 2 weeks before start of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- C1-inhibitor (Type: EXPERIMENTAL): One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
- Saline (Type: PLACEBO_COMPARATOR): One gift of intravenous administration of 0.9% NaCl during one hour.
- Antibiotics (Type: EXPERIMENTAL): broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Two Dose Epidural Morphine for Post-cesarean Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing cesarean section under epidural anesthesia.~Exclusion Criteria:~* Emergent cesarean section~* Coagulopathy~* Failed epidural anesthesia or patchy block~* General anesthesia~* Use of epidural chloroprocaine~* Allergy or contraindication to Non-steroidal anti-inflammatory drug (NSAIDs)~* Severe opioid side effects~* History of chronic opioid use~* History of chronic pain~* History of obstructive sleep apnea~* Morbid obesity (Body Mass Index (BMI)\>45 kg/m2)~* Height under 4' 10 (147 cm)~* Documented dural puncture by the epidural (Tuohy) needle~* Preeclampsia~* Other significant medical disease (American Society of Anesthesiologists (ASA) 3 or more).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Epidural Morphine (Type: ACTIVE_COMPARATOR): Group receiving 3mg epidural morphine, 24 hours after the initial dose
- Epidural Saline (Type: PLACEBO_COMPARATOR): Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of initial or recurrent anal or vulvar high-grade squamous intraepithelial lesion (AIN2/3 or VIN2/3) diagnosed on or after 1/1/2014; study pathologist will use p16 staining as needed to rule out low-grade squamous intraepithelial lesion (LSIL) disease~* \>= 2 months since last therapy for HSIL~* No clinical evidence of HSIL on screening examination; if HSIL is suspected, a biopsy will be done to exclude HSIL; patients whose screening visit reveals HSIL on biopsy, may be re-screened \>= 2 months after therapy~* Resident in the catchment area of the clinics and willing to attend up to 8 clinic visits for a 36-month period~* Sexually active women of child-bearing potential must be willing to use effective contraception through month 7 of the study~* If human immunodeficiency virus (HIV) positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollment~* Ability to give informed consent~* Willingness to sign medical records release form and tissue release form~Exclusion Criteria:~* Currently pregnant~* Chemotherapy (current, within the last month, or anticipated in the next 7 months)~* Prior history of invasive HPV-related anogenital cancer (cervical, vaginal, vulvar, penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior cancer at other sites (including most of oral cavity) or larynx are not exclusions~* Unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer)~* Prior HPV vaccination~* Known allergy or intolerance to lidocaine~* Currently participating in an interventional research study related to HPV, except the Anal Cancer HSIL Outcomes Research (ANCHOR) study (NCT02135419)~* Any other condition which, in the opinion of the investigator, may compromise the subject's ability to follow study procedures and safely complete the study

- Gender: ALL
- Minimum Age: 27 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (recombinant human papillomavirus nonavalent vaccine) (Type: EXPERIMENTAL): Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive placebo IM at baseline, 2 months, and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: High-Flow in Hypercapnic Stable COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with COPD (FEV1/FVC \< 70%) and long term indication for home NIV for initiated at least 3 months prior the inclusion.~* Compliance with NIV (less than 5 hours and more than 1 hour) per night on average during the last 3 months prior to inclusion.~* Naïve to Nasal High Flow (NHF) therapy, i.e. having not used NHF in the last 6 months prior to inclusion.~* Able to understand, follow objectives and methods of protocol in French language.~* Patient affiliated to social security insurance or beneficiary of social health insurance.~* Willing and able to give written Informed Consent and to comply with the requirements of the study protocol.~Exclusion Criteria:~* Significant uncontrolled cardiac disease (investigator judgment), and/or Left Ventricular Ejection Fraction (LVEF) \< 45%.~* Known co-existing obstructive sleep apnea requiring expiratory pressure above 6 cmH20.~* Severe nasal obstruction, previous upper airway surgery preventing the usage of NHF, or, at the discretion of investigator, any other contraindication for using the NHF.~* Patients who are unable or unwilling to give informed consent.~* Participating in another research study.~* Patient protected by the Law, under guardianship or curators.~* Pregnancy and nursing mothers~* Patient not covered by a health insurance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Non Invasive Ventilation device group (Type: ACTIVE_COMPARATOR): The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
- Nasal High Flow (MyAirvo) device group (Type: EXPERIMENTAL): The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feeding Intolerance in Formula-Fed Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria for Stage 1:~* Singleton full term birth with birth weight of \> 2500g.~* Infant between 0 and 60 days of age.~* Discontinuation of medications that might affect gastrointestinal (GI) tolerance.~* Infant is exclusively formula-fed a full-lactose, intact cow milk protein-based infant formula (CMF) for less than 7 days prior to enrollment.~Inclusion Criteria for Stage 2:~* Infant was fed according to protocol in Stage 1 of the study.~* Infant was identified as being fussy using the Intolerance Assessment Tool in Stage 1.~Exclusion Criteria:~Exclusion Criteria for Stage 1:~* Chromosomal or major congenital anomalies.~* Suspected or known metabolic or physical diseases affecting infant feeding and/or metabolism.~* Hospitalization, other than for delivery, prior to enrollment.~* Severe uncontrolled eczema, visible bloody stools or milk protein allergy prior to enrollment.~* More than 1 substitution of an infant formula other than full-lactose, intact cow milk formula (CMF) since birth.~* Use of a prokinetic drug within 7 days before enrollment.~Exclusion Criteria for Stage 2:~* Infant's intolerance symptom was caused by another reason, for example known infection/illness, food allergy, or response to vaccination(s).~* Infant has immunization(s) within 3 days of enrollment in Stage 2.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Days
- Healthy Volunteers: t

Study Arms:
- Partially Hydrolyzed Infant Formula (Type: EXPERIMENTAL): Fed ad lib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Delivery Systems: Research & Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be enrolled veteran who smokes.~Exclusion Criteria:~* Any event or condition that could be exacerbated by the local effects of nicotine treatments (e.g., throat or stomach problems; any kind of wheezing from a condition or medication)~* other criteria as determined by PI and study physicians~* reactions to menthol (inhaler) or to aspartame (lozenge)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Nicotine Replacement Treatment (NRT) Sampling (Type: ACTIVE_COMPARATOR): Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device).
- NRT Computer Learning (Type: SHAM_COMPARATOR): Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transanal Decompression Tube Versus Stent for Acute Malignant Left-sided Colonic and Rectal Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. definite diagnosis of left-side colonic or rectal obstruction;~2. symptomatic colonic obstruction for less than 1 week;~3. colonic obstruction caused by a histologically proven malignant colonic tumor~Exclusion Criteria:~1. suspected benign colonic or rectal obstruction;~2. right-side colonic obstruction;~3. patients with signs of peritonitis;~4. dysfunction of blood coagulation, active bleeding, active infection, and significant cardiac or pulmonary disease;~5. patients who do not want to undergo surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Transanal decompression tube (Type: OTHER): Patients undergo placement of the transanal decompression tube as a bridge to surgery
- Stent (Type: OTHER): Patients undergo placement of the stent as a bridge to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged between 18 years and 70 years old.~* Pathologically confirmed metastatic triple negative breast cancer (TNBC). Paraffin-embedded tissue were available from metastatic or primary sites to confirm its TNBC status or for further translational research. TNBC was defined as ER-, PR-, and HER2-.~* Metastatic TNBC should not be treated with more than 1-line for metastatic disease.~* Patients can not be treated with carboplatin in the metastatic setting.~* For patients received carboplatin treatment in the adjuvant setting, they should have at least one year disease interval between last dosage of carboplatin and trial recruiting.~* Patients had at least one measurable lesion according to RECIST criteria version 1.1.~* ECOG Performance Status (PS) of 0-1.~* Adequate liver and renal organ function.~* Dated and signed IEC/IRB-approved informed consent.~Exclusion Criteria:~* More than 1 one therapy for metastatic TNBC, Patients may receive bisphosphonates and other therapies to treat bone metastases.~* Less than four weeks since last radiotherapy.~* Pregnancy or lactation or unwillingness to use adequate method of birth control.~* Active or uncontrolled infection.~* Hypersensitivity to carboplatin or decitabine~* Male breast cancer.~* Treated with any DNA demethylating agents~* Young patients with pregnancy or lactation or unwillingness to use adequate method of birth control.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DC (Type: EXPERIMENTAL): DNA demethylating agent decitabine plus carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues